FIELD: medicine.
SUBSTANCE: evaluation of additional risk factors - measuring the epicardial fatty tissue thickness, blood leptin, lipoprotein A and glucose is followed by mathematical processing of the numerical values of the risk factors to calculate a probability of restenosis by formula: P=[exp(-8.0248+0.0893·X1+0.00354·X2+0.1397·X3+1.1194·X4+0.3286·X5+0.0665·X6)]/[1+exp(-8.0248+0.0893·X1+0.00354·X2+0.1397·X3+1.1194·X4+0.3286·X5+0.0665·X6)], wherein P is the probability of restenosis, %, X1 is a patient's leptin, ng/ml; X2 is lipoprotein A, mg/l; X3 is the epicardial fatty tissue thickness, millimetres; X4 is high-density lipoprotein cholesterol, mmole/l; X5 is blood glucose, mmole/l; X6 is interleukin-6, pcg/ml; -8.0248 is the absolute term of the equation. The invention enables more accurate prediction of the risk of developing restenosis following coronary stenting in patients with ischemic heart disease.
EFFECT: effectiveness of the presented method and its applicability in practical healthcare.
1 tbl, 2 ex, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE RISK OF DEVELOPING DIASTOLIC DYSFUNCTION OF THE LEFT VENTRICLE IN OBESE PATIENTS | 2021 |
|
RU2774023C1 |
| METHOD FOR ASSESSING THE RISK OF DEVELOPING ADVERSE OUTCOMES WITHIN THE FIRST YEAR FOLLOWING THE PERCUTANEOUS CORONARY INTERVENTION WITH STENTING IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE | 2018 |
|
RU2692257C1 |
| METHOD OF PREDICTING THE RISK OF DEVELOPING CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH ABDOMINAL OBESITY WITH A STABLE COURSE OF CORONARY HEART DISEASE COMPLICATED BY CHRONIC HEART FAILURE II-III CLASS, WHO UNDERWENT MYOCARDIAL REVASCULARIZATION | 2022 |
|
RU2798728C1 |
| METHOD FOR DETERMINING THE RISK OF RAPIDLY PROGRESSIVE ATHEROSCLEROSIS IN PATIENTS WITH CORONARY HEART DISEASE | 2022 |
|
RU2789003C1 |
| METHOD FOR FORECASTING THE ONE-YEAR RISK OF DEVELOPMENT OF ADVERSE CARDIOVASCULAR EVENTS AFTER STENTING OF CORONARY ARTERIES IN PATIENTS WITH CORONARY HEART DISEASE WITH METABOLIC SYNDROME WITHOUT INSULIN RESISTANCE | 2017 |
|
RU2663496C1 |
| METHOD FOR RESTENOSIS DEVELOPMENT PREDICTION IN PATIENTS WITH STABLE EXERTIONAL ANGINA FOLLOWING CORONARY STENTING | 2020 |
|
RU2724279C1 |
| METHOD OF ESTIMATING RISK OF DEVELOPMENT OF UNFAVOURABLE CARDIOVASCULAR EVENTS IN PATIENTS WITH ISCHEMIC HEART DISEASE SUBJECTED TO ENDOVASCULAR MYOCARDIUM REVASCULARISATION DURING ONE YEAR AFTER INTERFERENCE | 2010 |
|
RU2444297C1 |
| DIAGNOSTIC TECHNIQUE FOR DISPOSITION TO ATHEROSCLEROSIS PROGRESSION IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASES BY PERIPHERAL BLOOD INTERLEUKIN-10-PRODUCING LYMPHOCYTE COUNT | 2014 |
|
RU2575791C1 |
| METHOD FOR PREDICTING DEVELOPMENT OF RESTENOSIS OF CORONARY ARTERY AFTER STENTING WITH BARE METAL OR DRUG-ELUTING STENT IN PATIENTS WITH ISCHEMIC HEART DISEASE | 2020 |
|
RU2748010C1 |
| METHOD FOR STENT RESTENOSIS PREDICTION IN PATIENTS WITH ISCHEMIC HEART DISEASE 6 MONTHS AFTER CORONARY STENTING | 2019 |
|
RU2695782C1 |
